StockData

Enanta Pharmaceuticals vs Wave Life Sciences

ENTA and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENTA and WVE compare

Wave Life Sciences is the larger company, worth 1.8 times as much as Enanta Pharmaceuticals ($566M against $311M).

Enanta Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −96.9% compared with −297% at Wave Life Sciences.

Wave Life Sciences scores higher on the StockData Score (10 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENTAWVE
Size and price
Market cap$311M$566M
Share price$10.67$2.87
Change, 1 year−9.0%−57.0%
Change, 5 years−88.4%−28.1%
Beta (5Y)1.471.84
Employees120317
StockData Score
Total score210 (better)
Valuation score03 (better)
Growth score01 (better)
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S4.8× (better)8.0×
P/B3.1×1.4× (better)
FCF yield−11.9% (better)−36.8%
Fair value$9.66$5.23
Margin of safety−10.5%45.1% (better)
Growth
Revenue growth, 5Y average−11.8%16.3% (better)
Profitability
Operating margin−90.0% (better)−321%
Net margin−96.9% (better)−297%
FCF margin−56.6% (better)−294%
Return on equity−70.1% (better)−80.0%
Financial health
Debt / equity–0.00
Interest coverage−4.5×–
Current ratio3.768.38 (better)
Altman Z-score−1.00 (better)−1.27
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.6%92.6%
Held by insiders7.9%23.1%
Insider net buying, 12 months−$183K$66.5M (better)
Superinvestors holding–1
Short interest, % of float6.9%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.